There’s a lot to be optimistic about in the Technology sector as 2 analysts just weighed in on Infinera (INFN – Research Report) and Cellebrite DI (CLBT – Research Report) with bullish sentiments.
Infinera (INFN)
Craig-Hallum analyst Christian Schwab maintained a Buy rating on Infinera today. The company’s shares closed last Wednesday at $6.25.
According to TipRanks.com, Schwab is a 5-star analyst with an average return of
Infinera has an analyst consensus of Strong Buy, with a price target consensus of $7.17, implying a 23.0% upside from current levels. In a report issued on April 1, Stifel Nicolaus also maintained a Buy rating on the stock with a $7.00 price target.
See today’s best-performing stocks on TipRanks >>
Cellebrite DI (CLBT)
Craig-Hallum analyst Jeff Van Rhee maintained a Buy rating on Cellebrite DI today. The company’s shares closed last Wednesday at $11.09.
According to TipRanks.com, Rhee is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cellebrite DI with a $13.38 average price target, which is a 24.3% upside from current levels. In a report issued on March 28, Needham also maintained a Buy rating on the stock with a $13.50 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on INFN:
- Fabrinet upgraded to Outperform from Market Perform at Northland
- DZS, Infinera to demo ICE-X coherent pluggable solutions
- Infinera to showcase advances in optical networking solutions at OFC 2024
- Infinera, Orange International Network establish long-term partnership
- Infinera Addresses Delay in Annual Report and Nasdaq Compliance
